Clinical Trial Update: Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

This document reports on a Phase 1/2 trial of patupilone (EPO 906) in patients with recurrent or progressive glioblastoma, now completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Patupilone (epothilone B)

Snippet

Sponsor: University of Zurich | Conditions: Recurrent Glioblastoma Planned for Reoperation | Phase 1, Phase 2 | Status: COMPLETED